Options for Stage II Melanoma: Making the Decision That’s Right For You
Resource for Oncologists: Understanding Stage II Melanoma
A melanoma diagnosis can evoke a range of emotions for patients and their families. For those diagnosed with Stage II melanoma—a deeper melanoma that may or may not be ulcerated and does not involve the lymph nodes—surgical removal is typically the primary treatment approach. However, concerns about potential recurrence or spread after surgery are common among patients.
As a healthcare provider, it’s essential to discuss the options available for managing Stage II melanoma with your patients. After surgery, there are generally two approaches to consider:
- Active Surveillance: This strategy involves closely monitoring the patient for signs of recurrence without administering additional treatment. It allows for timely intervention if any changes occur.
- Adjuvant Therapy: This treatment may be recommended to help decrease the risk of melanoma returning or spreading after surgical removal.
To facilitate these discussions, we have collaborated with two leading experts in the field to provide a comprehensive Q&A resource on Stage II melanoma treatment.
Expert Insights:
Dr. Geoffrey Lim, a dermatologic surgeon at SkinMed Institute in Lone Tree, Colorado, conducted an interview with Dr. Jason Luke, Associate Professor of Medicine at the University of Pittsburgh Medical Center and a prominent medical oncologist involved in significant adjuvant therapy research.
In this Q&A, they cover essential topics, including:
- Eligibility criteria for adjuvant therapy in Stage II melanoma patients
- The advantages and disadvantages of adjuvant therapy compared to active surveillance
- What are the potential side effects of adjuvant therapy?
- What is the method of administration?
We encourage you to share this resource with your patients to help them better understand their options and make informed decisions in partnership with your oncology care team.